AP2064A - Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors - Google Patents

Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Info

Publication number
AP2064A
AP2064A AP2005003452A AP2005003452A AP2064A AP 2064 A AP2064 A AP 2064A AP 2005003452 A AP2005003452 A AP 2005003452A AP 2005003452 A AP2005003452 A AP 2005003452A AP 2064 A AP2064 A AP 2064A
Authority
AP
ARIPO
Prior art keywords
pyrazolo
preparation
kinase inhibitors
quinazoline derivatives
quinazoline
Prior art date
Application number
AP2005003452A
Other languages
English (en)
Other versions
AP2005003452A0 (en
Inventor
Gabriella Traquandi
Maria Gabriella Brasca
Roberto D'alessio
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476970&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2064(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of AP2005003452A0 publication Critical patent/AP2005003452A0/xx
Application granted granted Critical
Publication of AP2064A publication Critical patent/AP2064A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2005003452A 2003-05-22 2004-04-27 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors AP2064A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47266103P 2003-05-22 2003-05-22
PCT/EP2004/050612 WO2004104007A1 (en) 2003-05-22 2004-04-27 Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors

Publications (2)

Publication Number Publication Date
AP2005003452A0 AP2005003452A0 (en) 2005-12-31
AP2064A true AP2064A (en) 2009-10-30

Family

ID=33476970

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003452A AP2064A (en) 2003-05-22 2004-04-27 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Country Status (36)

Country Link
US (8) US7482354B2 (me)
EP (1) EP1636236B1 (me)
JP (1) JP5043432B2 (me)
KR (1) KR101084871B1 (me)
CN (2) CN1826343A (me)
AP (1) AP2064A (me)
AR (2) AR044543A1 (me)
AU (1) AU2004240772B2 (me)
BR (2) BRPI0410563B8 (me)
CA (1) CA2526578C (me)
CO (1) CO5721006A2 (me)
CR (1) CR8102A (me)
CY (1) CY1114708T1 (me)
DK (1) DK1636236T3 (me)
EA (1) EA010904B1 (me)
EC (1) ECSP056194A (me)
ES (1) ES2436524T3 (me)
GE (1) GEP20094664B (me)
HR (1) HRP20050967B8 (me)
IL (1) IL172046A (me)
IS (1) IS2939B (me)
ME (1) ME00142B (me)
MX (1) MXPA05012573A (me)
MY (1) MY142019A (me)
NO (1) NO334992B1 (me)
NZ (1) NZ543661A (me)
OA (1) OA13170A (me)
PL (1) PL1636236T3 (me)
PT (1) PT1636236E (me)
RS (2) RS20050944A (me)
SI (1) SI1636236T1 (me)
TN (1) TNSN05298A1 (me)
TW (1) TWI349672B (me)
UA (1) UA80763C2 (me)
WO (1) WO2004104007A1 (me)
ZA (1) ZA200509486B (me)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101084871B1 (ko) * 2003-05-22 2011-11-21 네르비아노 메디칼 사이언시스 에스.알.엘. 피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EA014231B1 (ru) 2006-02-10 2010-10-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Комбинации, включающие ингибитор cdk и антитело фактора роста или антимитотик
JP2009536180A (ja) * 2006-05-09 2009-10-08 ノバルティス アクチエンゲゼルシャフト 鉄キレート剤と抗新生物剤を含む組合せ剤およびそれらの使用
WO2007149395A2 (en) * 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
US7517882B2 (en) 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
PT2125822E (pt) 2006-12-21 2015-01-30 Nerviano Medical Sciences Srl Derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase
ZA200904912B (en) * 2006-12-21 2010-09-29 Nerviano Medical Sciences Srl Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
US8329711B2 (en) 2007-10-23 2012-12-11 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
CA2709202C (en) * 2007-12-19 2013-04-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
MX2010010975A (es) * 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
TWI426074B (zh) * 2008-04-30 2014-02-11 Nerviano Medical Sciences Srl ５－（２－胺基－嘧啶－４－基）－２－芳基－１ｈ－吡咯－３－羧醯胺之製造方法
ES2572360T3 (es) * 2008-06-26 2016-05-31 Servier Lab Pirazolo-quinazolinas como moduladores de la actividad de la proteína quinasa
JP5579715B2 (ja) * 2008-07-29 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ
CN102105151B (zh) * 2008-07-29 2013-12-18 内尔维阿诺医学科学有限公司 Cdk抑制剂在治疗神经胶质瘤中的应用
JP5579724B2 (ja) * 2008-10-17 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環
CN102223885B (zh) 2008-11-24 2013-04-03 内尔维阿诺医学科学有限公司 用于治疗间皮瘤的cdk抑制剂
IT1395724B1 (it) * 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
JP5650193B2 (ja) * 2009-03-20 2015-01-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 胸腺腫の治療のためのキナーゼ阻害剤の使用
JP5901020B2 (ja) * 2009-04-22 2016-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療用ＰＩ３−キナーゼ阻害薬としてのチア−トリアザ−ａｓ−インダセン
JP5801285B2 (ja) * 2009-04-29 2015-10-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｃｄｋ阻害物質の塩
AR076784A1 (es) * 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
ES2553114T3 (es) * 2009-07-29 2015-12-04 Nerviano Medical Sciences S.R.L. Sales de inhibidor de plk
KR20120117905A (ko) * 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 프로테아좀 활성을 향상시키는 조성물 및 방법
US8735386B2 (en) * 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
JP5997143B2 (ja) * 2010-07-30 2016-09-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ タンパク質キナーゼ活性の調整剤としてのイソオキサゾロ−キナゾリン
US20140309244A1 (en) 2010-09-23 2014-10-16 Syngenta Participations Ag Novel microbiocides
MX2020005498A (es) * 2010-10-25 2021-08-26 G1 Therapeutics Inc Inhibidores de cdk.
CN103298816A (zh) * 2010-12-17 2013-09-11 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代的吡唑并-喹唑啉衍生物
US8916577B2 (en) * 2011-01-26 2014-12-23 Nerviano Medical Sciences S.R.L. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
JP5925809B2 (ja) * 2011-01-26 2016-05-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用
WO2012117021A2 (en) 2011-03-03 2012-09-07 Syngenta Participations Ag Novel microbiocidal oxime ethers
PT2937349T (pt) 2011-03-23 2017-03-24 Amgen Inc Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
LT2707101T (lt) 2011-05-12 2019-05-27 Proteostasis Therapeutics, Inc. Proteostazę reguliuojantys agentai
WO2013092460A1 (en) 2011-12-20 2013-06-27 Syngenta Participations Ag Cyclic bisoxime microbicides
JP6128133B2 (ja) * 2012-01-23 2017-05-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｇｆ−１ｒ／ｉｒ阻害剤としての５，８−ジヒドロ−６ｈ−ピラゾロ［３，４−ｈ］キナゾリン
EP2641901A1 (en) 2012-03-22 2013-09-25 Syngenta Participations AG. Novel microbiocides
EP2917214B1 (en) 2012-11-07 2019-08-28 Nerviano Medical Sciences S.r.l. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
US9487530B2 (en) 2013-03-15 2016-11-08 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
RU2692479C2 (ru) 2014-04-07 2019-06-25 Недерлэндс Транслэшинал Рисерч Сентер Б.В. (5,6-дигидро)пиримидо[4,5-е]индолизины
US20150297607A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy
ES2873959T3 (es) 2014-05-28 2021-11-04 Piramal Entpr Ltd Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
MX2018000657A (es) 2015-07-17 2018-09-06 Pasteur Institut Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite.
AU2017295038B2 (en) 2016-07-15 2022-09-22 Centre Hospitalier Sainte Anne Paris 5-hydroxytryptamine 1B receptor-stimulating agent for skin and/or hair repair
CN113264935B (zh) * 2016-11-11 2022-09-20 上海海雁医药科技有限公司 吡啶胺取代的杂三环化合物及其中间体和医药上的用途
EP3652177A1 (en) 2017-07-11 2020-05-20 Nerviano Medical Sciences S.r.l. Pyrazolo-quinazoline derivatives as choline kinase inhibitors
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
CN111094291B (zh) * 2017-08-11 2022-06-21 晟科药业（江苏）有限公司 1h-吡唑并[4,3-h]喹唑啉类化合物作为蛋白激酶抑制剂
CN114423765A (zh) * 2019-09-05 2022-04-29 成都赛璟生物医药科技有限公司 异唑并[5,4-h]喹唑啉类化合物作为蛋白激酶抑制剂
WO2021084541A1 (en) * 2019-10-31 2021-05-06 Sol-Gel Technologies Ltd. Treatment of hair loss disorders with a topical egfr inhibitor
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN114685520A (zh) * 2020-12-25 2022-07-01 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2022143576A1 (zh) * 2020-12-31 2022-07-07 恒元生物医药科技(苏州)有限公司 一种吡唑并喹唑啉类化合物、其制备方法及应用
US20240140962A1 (en) * 2021-02-08 2024-05-02 Medshine Discovery Inc. 5,6-dihydrothieno[3,4-h]quinazoline compound
CN113527310B (zh) * 2021-07-30 2022-09-23 上海市肺科医院 用于减轻自身免疫性疾病患者不良炎性反应的小分子化合物及其应用
WO2023104178A1 (zh) * 2021-12-10 2023-06-15 山东绿叶制药有限公司 蛋白激酶抑制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2119975A (en) * 1936-08-26 1938-06-07 Beatrice S Nazel Fluid pressure hammer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3907220B2 (ja) * 1994-06-30 2007-04-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 複素環含有化合物
ES2203642T3 (es) 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
BR0013143A (pt) 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
KR100904157B1 (ko) 2000-08-10 2009-06-23 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물
DE60132702T2 (de) * 2000-08-11 2009-03-19 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen
US20040019046A1 (en) 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
NZ527767A (en) 2001-01-26 2004-11-26 Pharmacia Italia S Chromane derivatives, process for their preparation and their use as antitumor agents
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
CA2456939A1 (en) * 2001-08-10 2003-02-20 Pharmacia Corporation Carbonic anhydrase inhibitors
ES2357502T3 (es) 2001-09-26 2011-04-27 Pfizer Italia S.R.L. Derivados de aminoindazol activos como inhibidores de quinasa, procedimiento para su preparación y composiciones farmaceuticas que los contienen.
AU2003225580A1 (en) * 2002-02-19 2003-09-09 Pharmacia Corporation Tricyclic pyrazole derivatives for the treatment of inflammation
KR101084871B1 (ko) 2003-05-22 2011-11-21 네르비아노 메디칼 사이언시스 에스.알.엘. 피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도
PT2125822E (pt) * 2006-12-21 2015-01-30 Nerviano Medical Sciences Srl Derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2119975A (en) * 1936-08-26 1938-06-07 Beatrice S Nazel Fluid pressure hammer

Also Published As

Publication number Publication date
CN102079746A (zh) 2011-06-01
AU2004240772A1 (en) 2004-12-02
AR044543A1 (es) 2005-09-21
US20150158876A1 (en) 2015-06-11
TW200505924A (en) 2005-02-16
CO5721006A2 (es) 2007-01-31
US20170190714A1 (en) 2017-07-06
IS8132A (is) 2005-11-18
BR122019010200B8 (pt) 2021-07-27
NO20055496L (no) 2006-02-14
US20190194214A1 (en) 2019-06-27
AU2004240772B2 (en) 2011-04-28
IL172046A (en) 2017-03-30
ECSP056194A (es) 2006-04-19
TWI349672B (en) 2011-10-01
EA010904B1 (ru) 2008-12-30
JP5043432B2 (ja) 2012-10-10
UA80763C2 (en) 2007-10-25
ME00142B (me) 2010-10-10
AP2005003452A0 (en) 2005-12-31
RS20050944A (en) 2008-06-05
BRPI0410563B8 (pt) 2021-05-25
US20210300935A1 (en) 2021-09-30
DK1636236T3 (da) 2013-12-09
US20090124605A1 (en) 2009-05-14
PL1636236T3 (pl) 2014-02-28
HRP20050967B1 (hr) 2014-03-28
MY142019A (en) 2010-08-16
US20130338148A1 (en) 2013-12-19
MEP25908A (en) 2010-06-10
EP1636236B1 (en) 2013-10-09
HRP20050967B8 (hr) 2014-04-25
NZ543661A (en) 2009-05-31
AR102722A2 (es) 2017-03-22
US8541429B2 (en) 2013-09-24
HRP20050967A2 (en) 2007-05-31
US9464090B2 (en) 2016-10-11
NO20055496D0 (no) 2005-11-21
IS2939B (is) 2016-03-15
US8981089B2 (en) 2015-03-17
JP2007502851A (ja) 2007-02-15
NO334992B1 (no) 2014-08-18
ES2436524T3 (es) 2014-01-02
CA2526578C (en) 2012-01-24
SI1636236T1 (sl) 2014-01-31
US9637497B2 (en) 2017-05-02
BRPI0410563A (pt) 2006-06-20
OA13170A (en) 2006-12-13
US10280176B2 (en) 2019-05-07
US7482354B2 (en) 2009-01-27
EP1636236A1 (en) 2006-03-22
KR20060015294A (ko) 2006-02-16
BR122019010200B1 (pt) 2020-12-15
ZA200509486B (en) 2008-09-25
CN1826343A (zh) 2006-08-30
CA2526578A1 (en) 2004-12-02
MXPA05012573A (es) 2006-02-22
BRPI0410563B1 (pt) 2020-12-01
US20070185143A1 (en) 2007-08-09
GEP20094664B (en) 2009-04-10
TNSN05298A1 (fr) 2007-07-10
CR8102A (es) 2006-08-09
US20170050972A1 (en) 2017-02-23
CY1114708T1 (el) 2016-10-05
EA200501849A1 (ru) 2006-06-30
PT1636236E (pt) 2013-12-16
KR101084871B1 (ko) 2011-11-21
WO2004104007A1 (en) 2004-12-02
RS52899B (en) 2014-02-28

Similar Documents

Publication Publication Date Title
AP2064A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
SI2125822T1 (sl) Substituirani pirazolo-kinazolinski derivati, postopek za njihovo pripravo in njihova uporaba kot inhibitorji kinaze
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
HK1093503A1 (en) Pyrido 2, 1-a-isoquinoline derivatives as ddp-IV inhibitors
ZA201202026B (en) PYROLO[2,3-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
IL179424A0 (en) Substituted oxazole -benzoisothiazole dioxide derivatives, process for their preparation and their use
HUP0402245A3 (en) Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
HK1089768A1 (en) Indolone-acetamide derivatives, processes for preparing them and their uses
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
EP1689393A4 (en) PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS
IL182054A0 (en) Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
IL175300A0 (en) Indirubin-type compounds, compositions, and methods for their use
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
EP1670466A4 (en) PREPARATION OF 1,6,7-TRISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
EP1590333A4 (en) GLYCOGENE SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR PREPARING THE SAME
HUP0500920A2 (en) Oxadiazole derivatives, process for their preparation and their use
PL378121A1 (pl) Sposób wytwarzania pirolotriazynowych inhibitorów kinazy
SI2020410T1 (sl) Derivati pirido(2,3-d)pirimidina, njihova priprava, njihova terapevtska uporaba
IL186062A (en) Indanyl-piperazine derivatives, method for preparing same and pharmaceutical compositions containing same
IL179076A0 (en) Azasugasr derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof